We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
-
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
Take action. -
Our programs are designed to provide relevant information to support people with bleeding disorders and their families with their ability to make informed choices.
Take a look. -
Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved.
Thanks to the Nagel Foundation and their generous support of NHF Idaho.
Shire recently announced that the U.S. Food and Drug Administration (FDA) has approved the company’s recombinant von Willebrand factor (rVWF) product VONVENDI®, for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD). The therapy had already been approved for the on-demand treatment and control of bleeding episodes in adults 18 and older who have VWD.
Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.
NHF's MASAC has issued the latest revision to their most comprehensive treatment document.
The designation is for people with hemophilia A without inhibitors.
NHF is expanding its work with the bleeding disorders community around the world.
Subscribe to Our Newsletter
Fill in the fields below to receive our email newsletter.
